BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 14597937)

  • 1. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS).
    Shlipak MG; Chaput LA; Vittinghoff E; Lin F; Bittner V; Knopp RH; Hulley SB;
    Am Heart J; 2003 Nov; 146(5):870-5. PubMed ID: 14597937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: the Heart and Estrogen-Progestin Replacement Study (HERS).
    Simon JA; Lin F; Vittinghoff E; Bittner V;
    Ann Epidemiol; 2006 Feb; 16(2):138-45. PubMed ID: 16039873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.
    Clearfield MB; Weis SE; Willis JM; Vasenius KA; McConathy WJ
    J Am Osteopath Assoc; 2002 Jul; 102(7):377-84. PubMed ID: 12138952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen plus progestin and the risk of coronary heart disease.
    Manson JE; Hsia J; Johnson KC; Rossouw JE; Assaf AR; Lasser NL; Trevisan M; Black HR; Heckbert SR; Detrano R; Strickland OL; Wong ND; Crouse JR; Stein E; Cushman M;
    N Engl J Med; 2003 Aug; 349(6):523-34. PubMed ID: 12904517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines.
    Shai I; Rimm EB; Hankinson SE; Curhan G; Manson JE; Rifai N; Stampfer MJ; Ma J
    Circulation; 2004 Nov; 110(18):2824-30. PubMed ID: 15492318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial.
    Nevitt MC; Felson DT; Williams EN; Grady D
    Arthritis Rheum; 2001 Apr; 44(4):811-8. PubMed ID: 11315920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
    Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
    Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of LDL/HDL cholesterol ratio as a predictor for coronary heart disease events in patients with heterozygous familial hypercholesterolaemia: a 15-year follow-up (1987-2002).
    Panagiotakos DB; Pitsavos C; Skoumas J; Chrysohoou C; Toutouza M; Stefanadis CI; Toutouzas PK
    Curr Med Res Opin; 2003; 19(2):89-94. PubMed ID: 12755140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-year study of estrogen alone versus combined with progestin in postmenopausal women with or without hypercholesterolemia.
    Sanada M; Nakagawa H; Kodama I; Sakasita T; Ohama K
    Metabolism; 2000 Jun; 49(6):784-9. PubMed ID: 10877207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.
    Otvos JD; Collins D; Freedman DS; Shalaurova I; Schaefer EJ; McNamara JR; Bloomfield HE; Robins SJ
    Circulation; 2006 Mar; 113(12):1556-63. PubMed ID: 16534013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.
    Chang TC; Lien YR; Chen M; Cheng SP; Chen RJ; Chow SN
    Acta Obstet Gynecol Scand; 2004 Jul; 83(7):661-6. PubMed ID: 15225192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors.
    Krobot KJ; Yin DD; Alemao E; Steinhagen-Thiessen E
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):37-45. PubMed ID: 15703504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of statin therapy in adults with coronary heart disease.
    Wilt TJ; Bloomfield HE; MacDonald R; Nelson D; Rutks I; Ho M; Larsen G; McCall A; Pineros S; Sales A
    Arch Intern Med; 2004 Jul; 164(13):1427-36. PubMed ID: 15249352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
    Grady D; Herrington D; Bittner V; Blumenthal R; Davidson M; Hlatky M; Hsia J; Hulley S; Herd A; Khan S; Newby LK; Waters D; Vittinghoff E; Wenger N;
    JAMA; 2002 Jul; 288(1):49-57. PubMed ID: 12090862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.
    Hulley S; Grady D; Bush T; Furberg C; Herrington D; Riggs B; Vittinghoff E
    JAMA; 1998 Aug; 280(7):605-13. PubMed ID: 9718051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A;
    Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.